TICKERNERD
Menu
IMNMIMNMHealthcare · Biotechnology

IMNM Stock Forecast: Immunome, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$29
+1.57% on the day

The 14 Wall Street analysts covering Immunome, Inc. hold a median 12-month price target of $36 — +26.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 33 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$3.2B
Ticker Nerd rank
33 / 100
Median analyst target
$36
Analysts covering
14
Total return, dividends reinvested
1W
+4.9%
1M
+25.2%
YTD
+32.8%
1Y
+186.6%
From 52W high
−4.4%
From 52W low
+217.2%
$9
$30
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

IMNM stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Immunome, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
33 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
96
Value
63
Quality
53
Volatility
49
Revisions
36
Accruals
32
Size
30
Growth
28
Issuance
23

Momentum (96): The shares have been drifting up relative to others.

Issuance (23): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

IMNM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IMNM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40Oct 25Jan 26Apr 26Jul 26IMNMHigh $40Median $36Low $30

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says14 analysts
14 Buy0 Hold0 Sell
Low $30Median $36High $40

The green dot is the last close — the median target sits +26.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
12 Aug 2026Truist SecuritiesMaintainsBuy$37 → $38
12 Aug 2026WedbushMaintainsOutperform$31 → $35
21 July 2026WedbushReiteratesOutperform$31
21 July 2026WedbushReiteratesOutperform—
12 June 2026WedbushReiteratesOutperform—
12 June 2026WedbushReiteratesOutperform$31
28 May 2026BarclaysInitiatesOverweight—
28 May 2026Truist SecuritiesMaintainsBuy—
15 May 2026Leerink PartnersMaintainsOutperform—
13 May 2026HC Wainwright & Co.ReiteratesBuy—
4 Mar 2026Craig-HallumMaintainsBuy—
4 Mar 2026Stephens & Co.MaintainsOverweight—
12 Feb 2026HC Wainwright & Co.InitiatesBuy—
15 Jan 2026WedbushReiteratesOutperform—
16 Dec 2025Evercore ISI GroupMaintainsOutperform—
16 Dec 2025GuggenheimMaintainsBuy—
16 Dec 2025Lake StreetMaintainsBuy—
1 Dec 2025Truist SecuritiesInitiatesBuy—
17 Nov 2025Stephens & Co.MaintainsOverweight—
22 Sept 2025Goldman SachsInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IMNM appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

IMNM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
11
Analysts cutting
1
Fundamentals

Immunome, Inc. (IMNM) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−11.7×

Cheaper than 93% of US stocks

Price / sales
466.7×

Cheaper than 2% of US stocks

Price / book
6.2×

Cheaper than 18% of US stocks

EV / EBITDA
−10.6×

Cheaper than 84% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
−100.0%

Higher than 1% of US stocks

Gross margin
—
Operating margin
−3228.8%

Higher than 4% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−64.0%

Higher than 18% of US stocks

Return on assets
−37.8%

Higher than 11% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

IMNM vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
IMNMImmunome, Inc.$3.2B
33
MBXMBX Biosciences, Inc.$3.2B
35
SLSSELLAS Life Sciences Group, Inc.$3.1B
65
ARQTArcutis Biotherapeutics, Inc.$3.1B
88
CLDXCelldex Therapeutics, Inc.$3.1B
31
TARSTarsus Pharmaceuticals, Inc.$3.1B
84
NAMSNewAmsterdam Pharma Co. NV$3.2B
42

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Immunome, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest IMNM news & analysis

Immunome: Maintaining My 'Strong Buy' Rating With 2 Catalysts On The Horizon

Seeking Alpha · 13 Aug 2026positive

The author maintains a "Strong Buy" rating on Immunome, citing FDA acceptance of varegacestat's NDA with a PDUFA date set for April 2027, and noting the diversified pipeline including IM-1021 in phase 1 with initial data expected in 2026.

Why it matters — IMNM watchers would care because the FDA acceptance of varegacestat's NDA and upcoming PDUFA date represent a major regulatory catalyst, while IM-1021's early-stage data could be a significant pipeline milestone in 2026.

Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update

Business Wire · 11 Aug 2026neutral

Immunome, Inc. reported its financial results for the quarter ended June 30, 2026, and provided a business update. The company stated it continues to execute its strategy of building a diversified targeted oncology company with multiple opportunities to bring needed therapies to patients.

Why it matters — This quarterly financial report and business update offers IMNM watchers insight into the company's progress on its targeted oncology pipeline and strategic execution.

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire · 6 Aug 2026neutral

Immunome announced that its Compensation Committee granted inducement awards on August 3, 2026, consisting of non-statutory stock options to purchase an aggregate of 176,500 shares of common stock to nine new employees under the company's 2024 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).

Why it matters — IMNM watchers would note this as a routine equity-based incentive arrangement to attract and retain nine newly hired employees, reflecting standard corporate governance under Nasdaq rules.

FAQ

Frequently asked questions about IMNM stock

What is the IMNM stock price forecast for 2026-2027?

The 14 Wall Street analysts covering Immunome, Inc. have a median 12-month price target of $36, with estimates ranging from $30 to $40. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is IMNM stock a buy right now?

Of the 14 analysts covering Immunome, Inc., 14 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Immunome, Inc. 33 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank IMNM?

As at 22 Aug 2026, Immunome, Inc. ranks 33 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (96 of 100).

Will IMNM stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts implies +26.2% from the last close, and Ticker Nerd's factor model ranks Immunome, Inc. 33 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the IMNM stock forecast for 2030?

No analyst covering Immunome, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IMNM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $30 to $40 over the next 12 months.

How has IMNM stock performed over the past year?

Immunome, Inc. returned +186.6% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Immunome, Inc. do?

Immunome Inc. is a biotechnology company specializing in highly innovative research and development within the life sciences sector.

What is the latest news on IMNM?

The most recent item we track (Seeking Alpha, 13 Aug 2026): "Immunome: Maintaining My 'Strong Buy' Rating With 2 Catalysts On The Horizon". The author maintains a "Strong Buy" rating on Immunome, citing FDA acceptance of varegacestat's NDA with a PDUFA date set for April 2027, and noting the diversified pipeline including IM-1021 in phase 1 with initial data expected in 2026.

Company

About Immunome, Inc.

Immunome Inc. is a biotechnology company specializing in highly innovative research and development within the life sciences sector. The primary focus of the company is to advance immunotherapy-based cancer treatments through its proprietary discovery engine that harnesses the immune system's natural capabilities. Immunome’s approach involves leveraging its unique antigen technology to identify novel targets and develop therapeutic antibodies, aimed at enabling the body's immune response to recognize and combat cancer more effectively. This cutting-edge focus places Immunome Inc. squarely at the forefront of the biologics market, with potential applications spanning various oncology therapies. Since its inception, the company has continually explored partnerships with academic institutions and other biotech firms, enhancing collaborative efforts to propel novel findings from the laboratory to clinical trials. Immunome’s efforts contribute significantly to the pharmaceutical and healthcare industries, underscoring the growing importance of targeted therapies and personalized medicine in addressing complex medical challenges. Based in Exton, Pennsylvania, Immunome Inc. represents a key player in translating breakthrough immunological insights into tangible healthcare solutions, emphasizing robust scientific innovation in combating one of the world's most persistent health issues.

CEO Dr. Clay B. Siegall Ph.D. · 247 employees · United States · https://immunome.com